Browsing Breast Cancer Research by author "Dowsett, Mitch"
Now showing items 21-40 of 45
-
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; et al. (2020-05)PURPOSE.—:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—:A ... -
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; et al. (2020-04)Purpose: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. Methods: A multidisciplinary ... -
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Xiao, T; Li, W; Wang, X; Xu, H; Yang, J; et al. (2018-07-09)Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER+) breast cancer, but the underlying mechanisms are largely unknown. We have identified C-terminal SRC kinase (CSK) as a critical ... -
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Dowsett, M; Ellis, MJ; Dixon, JM; Gluz, O; Robertson, J; et al. (2020-01)Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical ... -
Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab.
Willis, S; Polydoropoulou, V; Sun, Y; Young, B; Tsourti, Z; et al. (2018-01)Purpose The Herceptin Adjuvant study is an international multicenter randomized trial that compared 1 or 2 years of trastuzumab given every 3 weeks with observation in women with human epidermal growth factor 2-positive ... -
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; et al. (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to ... -
Impact of a panel of 88 SNPs on the risk of breast cancer in high risk women: Results from two randomised tamoxifen prevention trials
Cuzick, J; Brentnall, AR; Segal, C; Byers, H; Reuter, C; et al. -
Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study.
Busana, MC; Eng, A; Denholm, R; Dowsett, M; Vinnicombe, S; et al. (2016-09-26)Background Full-field digital mammography, which is gradually being introduced in most clinical and screening settings, produces two types of images: raw and processed. However, the extent to which mammographic density ... -
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
Dowsett, M; Lønning, PE; Davidson, NE (2016-05) -
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2019-04-06)BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, ... -
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett, M; Sestak, I; Regan, MM; Dodson, A; Viale, G; et al. (2018-07)Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with hormone receptor-positive breast cancer after 5 years of endocrine treatment without recurrence. We developed and validated ... -
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis, MJ; Suman, VJ; Hoog, J; Goncalves, R; Sanati, S; et al. (2017-04)Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 ... -
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2018-01-01)BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after ... -
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; et al. (2018-09-04)Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ... -
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; et al. (2016-09)Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ... -
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri, A; Smith, IE; Hills, M; Jones, RL; Johnston, SR; et al. (2017-07)Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 ... -
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
Brentnall, AR; Cuzick, J; Byers, H; Segal, C; Reuter, C; et al. (2016-08)A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict ... -
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Heindl, A; Sestak, I; Naidoo, K; Cuzick, J; Dowsett, M; et al. (2018-02)Background Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor-negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well ... -
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Sestak, I; Dowsett, M; Ferree, S; Baehner, FL; Cuzick, J (2016-08)Clinical variables and several gene signature profiles have been investigated for the prediction of (distant) recurrence in several trials. These molecular markers are significantly correlated with overall and late distant ...